Peripheral NOP receptor activation reduces CGRP-induced migraine pain as effectively as brain-penetrant treatment
A peripherally restricted NOP agonist (UFP-112) reduced CGRP-evoked periorbital allodynia equally to a brain-penetrant NOP agonist (AT-403) in mice, with N/OFQ inhibiting CGRP-induced cAMP in human Schwann cells—suggesting peripheral NOP targeting as a migraine strategy.
Quick Facts
What This Study Found
UFP-112 (peripheral) = AT-403 (brain-penetrant) for reducing CGRP-evoked PMA. N/OFQ internalized NOP and recruited Gαi at membrane + endosomes. N/OFQ attenuated CGRP-induced cAMP in human Schwann cells. NOP knockout: no baseline difference in CGRP sensitivity.
Key Numbers
How They Did This
CGRP-induced PMA in wild-type, NOP-/-, and CD-1 mice. NOP agonists (AT-403, UFP-112). HEK293 NOP signaling studies. Human Schwann cell cAMP assays.
Why This Research Matters
Peripheral-only NOP agonists could provide migraine relief without CNS side effects. The identification of Schwann cells as the cellular target bridges neuropeptide pharmacology with peripheral nerve biology.
The Bigger Picture
The NOP system represents a novel migraine target complementary to CGRP blockade. Peripheral NOP agonists could be developed as safe, effective migraine treatments without the CNS side effects that limit current analgesics.
What This Study Doesn't Tell Us
Mouse model. Schwann cell as cellular site needs in vivo confirmation. UFP-112 pharmacokinetics in humans unknown. Single pain model tested.
Questions This Raises
- ?Could NOP agonists be combined with anti-CGRP drugs for refractory migraine?
- ?Would NOP agonists help patients who do not respond to CGRP-targeting therapies?
- ?Are there other peripheral cell types where NOP-CGRP interaction is important?
Trust & Context
- Key Stat:
- Peripheral NOP = brain-penetrant A peripherally restricted NOP agonist matched the brain-penetrant compound for CGRP pain relief—enabling safer migraine treatment without CNS side effects
- Evidence Grade:
- Preclinical with in vivo pain model and in vitro mechanistic studies in human cells. Good translational evidence.
- Study Age:
- Published in 2025.
- Original Title:
- Activation of peripheral NOP receptors reduces periorbital mechanical allodynia evoked by CGRP in mice.
- Published In:
- British journal of pharmacology (2025)
- Authors:
- Sturaro, Chiara(2), Pola, Pietro(2), Argentieri, Michela(2), Frezza, Alessia, Marini, Matilde, De Logu, Francesco, Albanese, Valentina, Soukupova, Marie, Malfacini, Davide, Zaveri, Nurulain T, Nassini, Romina, Jensen, Dane D, Geppetti, Pierangelo, Calò, Girolamo, Ruzza, Chiara
- Database ID:
- RPEP-13691
Evidence Hierarchy
Frequently Asked Questions
What is the NOP receptor system?
The NOP (nociceptin/orphanin FQ) receptor is part of the opioid receptor family but does not respond to traditional opioid drugs. This study shows activating NOP receptors in peripheral nerves can counteract CGRP-induced migraine pain, offering a non-opioid approach to pain relief.
Why is peripheral-only treatment important?
Drugs that only work outside the brain avoid CNS side effects like sedation and cognitive impairment. This study proves that activating NOP receptors only in peripheral nerves (not the brain) is enough to relieve CGRP-induced migraine pain, enabling development of safer migraine drugs.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13691APA
Sturaro, Chiara; Pola, Pietro; Argentieri, Michela; Frezza, Alessia; Marini, Matilde; De Logu, Francesco; Albanese, Valentina; Soukupova, Marie; Malfacini, Davide; Zaveri, Nurulain T; Nassini, Romina; Jensen, Dane D; Geppetti, Pierangelo; Calò, Girolamo; Ruzza, Chiara. (2025). Activation of peripheral NOP receptors reduces periorbital mechanical allodynia evoked by CGRP in mice.. British journal of pharmacology. https://doi.org/10.1111/bph.70162
MLA
Sturaro, Chiara, et al. "Activation of peripheral NOP receptors reduces periorbital mechanical allodynia evoked by CGRP in mice.." British journal of pharmacology, 2025. https://doi.org/10.1111/bph.70162
RethinkPeptides
RethinkPeptides Research Database. "Activation of peripheral NOP receptors reduces periorbital m..." RPEP-13691. Retrieved from https://rethinkpeptides.com/research/sturaro-2025-activation-of-peripheral-nop
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.